Bristol-Myers Squibb acquires Cormorant Pharmaceuticals in deal worth up to $425 million

pharmafile | July 6, 2016 | News story | Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, cormorant 

Bristol-Myers Squibb (NYSE: BMY) has announced that it has acquired all outstanding capital stock of Sweden-based Cormorant Pharmaceuticals, granting it access to the company’s HuMax-IL8 antibody program.

The transaction includes upfront and near term contingent milestone payments of up to $95 million with further milestone payments of up to $425 million pending certain development and regulatory milestones.

The deal sees BMS acquire Cormorant’s lead candidate HuMax-IL8, a Phase I/II monoclonal antibody targeted against interleukin-8 (IL-8). This IL-8 protein is expressed by many solid tumours that suppresses the immune system and increases the ability of tumours to metastasise. By targeting IL-8, it is believed that HuMax-IL8 could boost immune response to become an efficacious combination therapy with existing cancer medicines.

Advertisement

Francis Cuss, chief scientific officer at BMS, says: “We believe combination therapy will be foundational to delivering the potential for long-term survival for patients, and the opportunity to develop the HuMax-IL8 antibody program together with our broad immuno-oncology pipeline enables us to accelerate the next wave of potentially transformational immunotherapies.”

Sean Murray

Related Content

Elekta and BMS partner for digital treatment for melanoma

Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan …

BMS acquires Mirati Therapeutics for $4.8bn

Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a …

BMS shares new research and development  plans at the company’s R&D day

Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, …

The Gateway to Local Adoption Series

Latest content